Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

1. Jazz Pharmaceuticals to participate in Jefferies Global Healthcare Conference on June 5, 2025. 2. Management will also join Goldman Sachs Healthcare Conference on June 11, 2025. 3. Audio webcasts of presentations will be accessible on their website for 30 days. 4. Company focuses on innovative therapies for serious diseases in various medical fields. 5. Jazz aims to enhance shareholder communication and investor engagement through events.

Corporate Developments

75

5m saved

Insight

Article

FAQ

Why Bullish?

Participation in high-profile investor conferences typically enhances visibility and investor confidence. Historical examples show similar events often lead to stock price increases for participating companies.

How important is it?

These conferences may reveal strategic directions and updates that can significantly impact investor perception. Increased transparency is expected, which can sway stock prices positively.

Why Short Term?

The immediate review of company performance and future plans at conferences can sway short-term investor sentiment. Promotions and visibility boost may create quick gains post-conference.

Related Companies

BLRX VRTX BIIB

DUBLIN, May 21, 2025 /PRNewswire/ --

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:

Jefferies Global Healthcare Conference on Thursday, June 5, 2025
Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025

Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:

Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948

SOURCE Jazz Pharmaceuticals plc